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introduction: Acute kidney injury (AKI) affects ~30% of hospitalized neonates. Critical 
to advancing our understanding of neonatal AKI is collaborative research among neona-
tologists and nephrologists. The Neonatal Kidney Collaborative (NKC) is an international, 
multidisciplinary group dedicated to investigating neonatal AKI. The AWAKEN study 
(Assessment of Worldwide Acute Kidney injury Epidemiology in Neonates) was designed 
to describe the epidemiology of neonatal AKI, validate the definition of neonatal AKI, 
identify primary risk factors for neonatal AKI, and investigate the contribution of fluid 
management to AKI events and short-term outcomes.
Methods and analysis: The NKC was established with at least one pediatric nephrol-
ogist and neonatologist from 24 institutions in 4 countries (USA, Canada, Australia, and 
India). A Steering Committee and four subcommittees were created. The database sub-
committee oversaw the development of the web-based database (MediData Rave™) 
that captured all NICU admissions from 1/1/14 to 3/31/14. Inclusion and exclusion 
criteria were applied to eliminate neonates with a low likelihood of AKI. Data collection 
included: (1) baseline demographic information; (2) daily physiologic parameters and care 
received during the first week of life; (3) weekly “snapshots”; (4) discharge information 
including growth parameters, final diagnoses, discharge medications, and need for renal 
replacement therapy; and (5) all serum creatinine values.
Abbreviations: AKI, acute kidney injury; AWAKEN, assessment of worldwide acute kidney injury epidemiology in neonates; 
CKD, chronic kidney disease; CRF, case report forms; CTSI, clinical and translational science institute; ELBW, extremely low 
birth weight; ELGAN, extremely low gestational age neonate; KDIGO, kidney disease: improving global outcomes; NICU, 
neonatal intensive care unit; NIH, National Institutes of Health; NKC, neonatal kidney collaborative; RIFLE, risk, injury, failure, 
loss- and end-stage; SCr, serum creatinine; TEFL, transepidermal fluid losses.
tablE 1 | neonatal aKi prevalence and mortality rates.
Prevalence  
(%)
Mortality aKi vs.  
no aKi (%)
reference
VLBWa 18 55 vs. 5 (8, 14)
40 14 vs. 4
ELBWb 13 70 vs. 22 (9)
Sick near term/term 18 22 vs. 0 (10)
Sepsis 26 70 vs. 25 (13)
Asphyxiated 38 14 vs. 2 (12)
ECMO 71 73 vs. 20c (11)
aVery low birth weight (VLBW) infants <1500 g.
bExtremely low birth weight (ELBW) infants <1000 g.
cExtracorporeal membrane oxygenation (ECMO).
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introduCtion
Over the last decade, the nephrology and critical care commu-
nities have repeatedly shown that acute kidney injury (AKI) in 
children (1, 2) and adults (3–7) portends poor short-term and 
long-term outcomes independent of severity of illness. The avail-
able short-term outcome data in neonates are similar: neonates 
with AKI have increased rates of mortality and longer hospital 
stays as compared to those without AKI (Table 1) (8–14). The 
prevalence of AKI reaches ~30% in neonates admitted to a 
tertiary level neonatal intensive care unit (NICU) (8–13, 14). 
However, prevalence estimates and data on short-term outcomes 
are solely derived from small retrospective, single-center studies. 
Moreover, little is known about the long-term consequences of 
neonatal AKI (15). Many significant questions, including how to 
best define, risk factors for, incidence of, association with other 
co-morbidities, and the short-term and long-term outcomes after 
AKI remain unanswered.
Critical to advancing the field of neonatal AKI is collaborative 
research among neonatologists and pediatric nephrologists. To 
foster this partnership, the National Institutes of Health (NIH) 
sponsored a multidisciplinary workshop on neonatal AKI in 
April 2013 (16, 17). Soon after, the Neonatal Kidney Collaborative 
(NKC) was formed to address the critical gaps in knowledge high-
lighted at the workshop. The NKC is an international working 
group composed of neonatologists and pediatric nephrologists 
committed to advancing the field of neonatal AKI research. The 
first mission of the NKC was to develop the infrastructure to func-
tion. The second mission of the NKC was the development of the 
AWAKEN study (Assessment of Worldwide Acute Kidney injury 
Epidemiology in Neonates), a large, retrospective cohort study 
designed with the following aims: (1) determine if the Kidney 
Disease: Improving Global Outcomes (KDIGO) AKI definition, 
adapted to neonates, is independently associated with mortality, 
length of stay, and discharge serum creatinine (sCr), (2) define 
the risk factors associated with neonatal AKI, (3) determine how 
fluid balance during the first few weeks of life relates to biochemi-
cal data and clinical outcomes, and (4) assess the performance of 
different definitions of AKI in neonates.
Assessment of Worldwide Acute Kidney injury Epidemiology 
in Neonates is the largest and most inclusive neonatal AKI study 
to date. Evaluation of these important questions will improve 
care and stimulate new research questions that will drive this 
field for many years. Collaborations will foster strong relation-
ships between neonatologists and pediatric nephrologists within 
and across centers. The infrastructure created to perform the 
AWAKEN study will position this group to conduct additional 
clinically relevant, hypothesis-driven studies aimed at improv-
ing the lives, health and well-being of patients at risk for kidney 
disease as the result of events during the newborn period. Here, 
we describe the formation of the NKC, the establishment of the 
AWAKEN cohort and database, future directions, and a few 
“lessons learned” in the process.
development of the neonatal Kidney 
Collaborative
The NKC is a voluntary, non-funded group made up of pediatric 
centers who agreed to ensure: (1) the participation of both a 
neonatologist and pediatric nephrologist from their institution 
and (2) local IRB approval. The NKC membership evolved from 
Ethics and dissemination: AWAKEN was proposed as human subjects research. 
The study design allowed for a waiver of informed consent/parental permission. NKC 
investigators will disseminate data through peer-reviewed publications and educational 
conferences.
discussion: The purpose of this publication is to describe the formation of the NKC, the 
establishment of the AWAKEN cohort and database, future directions, and a few “les-
sons learned.” The AWAKEN database includes ~325 unique variables and >4 million 
discrete data points. AWAKEN will be the largest, most inclusive neonatal AKI study to 
date. In addition to validating the neonatal AKI definition and identifying risk factors for 
AKI, this study will uncover variations in practice patterns related to fluid provision, renal 
function monitoring, and involvement of pediatric nephrologists during hospitalization. 
The AWAKEN study will position the NKC to achieve the long-term goal of improving the 
lives, health, and well-being of newborns at risk for kidney disease.
Keywords: aWaKEn, nKC, neonate, database, KdiGo, acute renal failure
tablE 2 | Participating institutions.
institution location  
(city, state, country)
Enrolled in  
aWaKEn (n)
% inborn Creatinine 
assay
Canberra Hospital Canberra, ACT, Australia 37 76 Jaffe
Children’s Hospital Colorado Denver, CO, USA 68 7 Enzymatic
Children’s Hospital at Montefiore Bronx, NY, USA 91 96 Enzymatic
Children’s National Medical Center Washington, DC, USA 86 1 Enzymatic
Cincinnati Children’s Hospital Medical Center Cincinnati, OH, USA 81 9 Enzymatic
Maimonides Medical Center Brooklyn, NY, USA 53 94 Enzymatic
Medanta –The Medicity Hospital Gurgaon Haryana, India 58 22 Jaffe
MetroHealth Medical Center Cleveland, OH, USA 69 100 Jaffe
Montreal Children’s Hospital/McGill University Montreal, Quebec, Canada 67 0 Jaffe
Nationwide Children’s Hospital Columbus, OH, USA 81 0 Enzymatic
Stony Brook Children’s Hospital Stony Brook, NY, USA 78 90 Enzymatic
Texas Children’s Hospital Houston, TX, USA 106 67 Enzymatic
Tufts University Boston, MA, USA 87 67 Enzymatic
University of Alabama at Birmingham Birmingham, AL, USA 59 63 Jaffe
University of British Columbia and Children’s and 
Women’s Health Center of British Columbia Branch
Vancouver, BC, Canada 104 63 Enzymatic
University of Iowa Iowa City, IO, USA 121 58 Enzymatic
University of Kentucky Lexington, KY, USA 116 54 Enzymatic
University of Miami Miami, FL, USA 192 90 Enzymatic
University of Michigan Ann Arbor, MI, USA 93 72 Jaffe
University of New Mexico Albuquerque, NM, USA 81 81 Enzymatic
University of Rochester Rochester, NY, USA 151 77 Enzymatic
University of Virginia Charlottesville, VA, USA 101 66 Jaffe
University of Washington Seattle, WA, USA 63 98 Both
Washington University in St. Louis St. Louis, MO, USA 120 1 Enzymatic
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professional relationships developed through previous clinical 
and research interactions including the 2013 NIH workshop 
“Neonatal AKI.” A current roster of participating institutions is 
included in Table 2.
The NKC infrastructure consists of the Steering Committee 
overseen by the Director and the co-chairpersons of the four sub-
committees (Figure  1). Each subcommittee (Protocol Commi-
ttee, Manuscript Committee, Database Committee, and Ancillary 
Studies Committee) is co-chaired by a pediatric nephrologist and 
a neonatologist, thereby assuring that the clinical expertise of 
both specialties is represented.
the aWaKEn Study
While research interest in neonatal AKI has increased greatly over 
the last 5 years, advances in clinical recognition, diagnosis, and 
supportive care for AKI in this population have lagged behind 
advances seen for adult and older pediatric patient groups (18). 
One major limitation to moving this field forward has been the 
lack of a standardized and validated definition of AKI in neonates 
similar to those used in adult and pediatric patients [e.g., risk, 
injury, failure, loss and end-stage RIFLE (19), KDIGO (20)]. The 
lack of a common definition has led to an inability to recognize 
AKI early and consistently across patients as well as an inability 
to pool or compare data across studies. In addition, the unique 
renal physiology of preterm and term infants creates challenges 
for the use of serum creatinine (sCr) as an AKI biomarker in 
these patients. Neonatal SCr initially reflects maternal values 
and then decreases over subsequent weeks after birth at different 
rates depending on gestational age. In addition, “normal” serum 
creatinine levels vary widely based on weight and gestational age. 
Before 2005, the majority of neonatal AKI studies used an arbitrary 
definition of AKI defined by a serum creatinine concentration 
(SCr) ≥1.5 mg/dl. In 2012, Jetton and Askenazi (21) proposed a 
standardized neonatal AKI definition based on the KDIGO defi-
nition for adults and children (Table 3) that identifies three levels 
of AKI severity based on graded changes in both serum creatinine 
and urine output. This and similar definitions have been utilized 
successfully in select neonatal patient populations (8, 10–12, 14, 
22, 23). Consensus at the NIH neonatal AKI workshop was that 
this definition, despite its limitations, was currently the most 
appropriate definition to adopt and validate (Michael Zappetelli, 
personal communication). The group stressed the need to con-
duct large multi-center studies to test the performance of this 
definition against clinically relevant outcomes and further refine 
the definition based on data generated from these large cohorts. 
Thus, the AWAKEN study was designed to fulfill this charge and 
determine the extent to which the definition of AKI is associated 
with the short-term outcomes of mortality, length of stay, and 
discharge sCr. Although the association of neonatal AKI with 
longer term outcomes is beyond the scope of the AWAKEN study, 
the data generated will provide the foundation for prospective 
follow-up studies and the groundwork for prospective studies of 
at-risk populations.
Similarly, fluid overload has been identified as a major 
risk factor for morbidity and mortality in adult and pediatric 
patients with AKI (24, 25), but has not been fully examined in 
the neonatal population. As with the study of sCr in this group, 
the unique physiology of neonates, especially premature and 
low-birth weight infants, creates challenges for applying concepts 
developed in older patients to this special group. In the first few 
days after birth, healthy term infants will lose around 7% of their 
weight. Depending on the amount of fluid provision, ambient 
FiGurE 1 | the Steering committee is composed of the director and the co-chairs of each of the sub-committees. The Protocol Committee was 
tasked to provide oversight and critique of the protocols submitted to the committee, both for the initial retrospective study (AWAKEN) and any future studies. It will 
also be charged with creating and submitting protocols to funding agencies and Institutional Review Boards. Other responsibilities include establishing rules for 
Primary Investigator designation and a system for group involvement for the establishment of future protocols. The Database Committee was charged with the 
development of the database, including the Manual of Procedures and Case Report Forms. Input was solicited from the NKC membership as to the data needed 
to answer the specific questions of interest for the AWAKEN study. These suggestions were collated and presented to the Steering Committee for final review. The 
myriad of data potentially available and the number of questions to be answered had the potential for an unwieldy and overwhelming amount of information. Data 
points that were included were thoroughly vetted by both nephrologists and neonatologists to balance the time of data collection with quality of the data elements. 
Once agreement was reached, in concert with the Data Management Center at Cincinnati Children’s Hospital Medical Center, electronic data forms were 
developed, tested, and finalized. The Manuscript Committee is responsible for initiating and developing abstracts for national and international meetings and 
manuscripts for submission to peer-reviewed journals. This committee will also review these abstracts and manuscripts prior to submission and provide the 
authors suggestions, as well as determine their suitability. The Ancillary Studies Committee will be responsible for developing rules on requesting use of data for 
ancillary studies and in developing these ideas into abstracts and manuscripts.
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temperature and humidity, gestational age, and kidney function, 
infants admitted to the NICU will have different amounts of 
weight losses due to changes in fluid balance over the first weeks 
of life (26).
Appropriate fluid balance is critical to the care of newborns. 
In  premature infants, mild fluid weight losses over the first 
week of life are desirable as high fluid intake can be associated 
with patent ductus arteriosus, bronchopulmonary dysplasia, 
cardiac failure, necrotizing enterocolitis, and intraventricular 
hemorrhage (27). Alternatively, inadequate fluid provision 
may cause hemodynamic dysfunction potentially resulting in 
AKI. However, in the extremely low-birth weight (ELBW) and 
extremely low gestational age neonate (ELGAN), fluid balance 
cannot be calculated in the same way as in older, larger neo-
nates, or pediatric patients [e.g., using documented intake and 
output volumes to calculate fluid overload or fluid deficits (28)]. 
Transepidermal fluid losses (TEFL) in the first week will vary 
considerably as a function of ambient humidity and are impos-
sible to measure in clinical practice. Although at birth TEFL in 
healthy full-term neonates is similar to that in older children and 
adults (4–8 g/m2/h), it is estimated to be 75 g/m2/h in neonates 
born at 23 weeks’ gestation (29). Humidified incubators simplify 
the management of fluids in these infants and help prevent 
extremes of electrolyte abnormalities. An important objective in 
AWAKEN will be to determine if variations in body weight are 
an adequate surrogate for fluid balance in this population rather 
than the reliance on recorded intake and output for calculation 
of fluid overload as is used in older patients. We also seek to 
determine whether fluid overload functions as a sign of kidney 
injury and increases the risk of morbidity and mortality as has 
been shown in older patient groups.
The primary hypothesis of AWAKEN is that neonatal AKI is 
common and associated with increased mortality, longer length 
of NICU stay and higher discharge serum creatinine, even after 
controlling for severity of illness, interventions and demographics. 
The two secondary hypotheses of AWAKEN include (1) maternal 
and infant risk factors can predict AKI and (2) fluid balance is 
associated with clinical outcomes (Table 4). Ultimately, the NKC 
will be positioned to test and validate the proposed neonatal 
AKI definition and compare it with other AKI definitions to 
determine which definition is the most accurate. We anticipate 
that the AWAKEN study can validate these hypotheses because 
of the large sample size and rich data set. This multicenter study 
will also uncover variations in practice patterns among NICUs 
in relation to fluid provision, renal function monitoring, bedside 
identification of AKI and AKI risk factors, and the involvement 
of pediatric nephrologists during inpatient hospitalization. 
Moreover, AWAKEN will provide important information regard-
ing critical time and data points necessary to build a meaningful 
prospective study in the future.
MEtHodS and analySiS
design
Assessment of Worldwide Acute Kidney injury Epidemiology in 
Neonates is a multi-center, international, retrospective cohort 
study. All neonates who fulfilled the inclusion and exclusion cri-
teria at each of the 24 participating centers from January 1, 2014 
until March 31, 2014 were enrolled (Figure 2). Detailed data 
collection continued until one of the following endpoints was 
reached: discharge to home, transfer to another facility or out of 
the NICU for escalating or convalescent care, death or 120 days 
tablE 4 | Primary hypotheses of aWaKEn.
Hypothesis #1: Neonatal AKI 
is associated with short-term 
risk, even when adjusted 
for gestational age at birth, 
birthweight, 5 min Apgar score, 
congenital renal anomalies, and 
severity of illness score
Survival of infants to discharge or 120 days 
of age (or to 36 weeks’ postmenstrual 
age in infants born preterm) is less likely in 
babies with the diagnosis of AKI
Length of stay is longer in infants with 
neonatal AKI
Discharge serum creatinine is higher in 
infants with neonatal AKI
Hypothesis #2: Maternal and 
infant risk factors predict AKI
Hypothesis #3: Fluid balance 
during the first week after birth 
is associated with short-term risk
Survival of infants to discharge or 120 days 
of age (or to 36 weeks’ postmenstrual 
age in infants born preterm) is less likely 
in babies with excessive fluid intake 
compared to output
Changes in weight are a better indication 
of fluid balance, especially in the preterm 
population, than difference between fluid 
intake and measured output
Length of stay is longer in infants with 
neonatal AKI
Pulmonary outcomes, as measured by 
time to extubation and development of 
bronchopulmonary dysplasia, are worse 
in infants with evidence of fluid overload
Discharge serum creatinine is higher in 
infants with fluid overload
tablE 3 | neonatal acute kidney injury KdiGo classification (21).
Stage Serum creatinine urine output
0 No change in sCr or rise <0.3 mg/dl > 1 ml/kg/h
1 sCr rise ≥0.3 mg/dl within 48 h or sCr rise 
≥1.5–1.9× reference sCra within 7 days
> 0.5 ml/kg/h and  
≤ 1 ml/kg/h
2 sCr rise ≥2–2.9× reference sCra >0.3 ml/kg/h and  
≤ 0.5 ml/kg/h
3 sCr rise ≥3× reference SCra or sCr 
≥2.5 mg/dlb or receipt of dialysis
≤ 0.3 ml/kg/h
Differences between the proposed neonatal AKI definition and KDIGO include:
aReference sCr will be defined as the lowest previous sCr value.
bsCr value of 2.5 mg/dl represents less than 10 ml/min/1.73m2.
FiGurE 2 | of the 4273 niCu admissions at the 24 participating 
institutions during the period 1/1/14–3/31/14, 2162 patients were 
enrolled. The majority of those not included did not receive at least 48 h of 
IV hydration and/or nutrition. The second most common reason for exclusion 
was admission to the NICU at greater than 14 days of age. Subjects may 
have been excluded for more than one reason and may be counted more 
than once in the “not enrolled” numbers.
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of age. Limited information was collected between 120 days and 




Twenty-four level 2–4 NICUs in the United States (n  =  20), 
Canada (n = 2), India (n = 1), and Australia (n = 1). A broad 
description of each institution is listed in Table 2, including the 
number of neonates enrolled in AWAKEN, the percentage of 
neonates born at that institution and the type of assay used to 
measure serum creatinine.
inclusion and Exclusion Criteria
All infants admitted from January 1, 2014 to March 31, 2014 who 
were ≤14 days of age and received at least 48 h of intravenous (IV) 
fluids as their primary source of hydration or nutrition (Table 5). 
Neonates who received IV fluids given solely for the administra-
tion of medications or line flushes were not included. The inclu-
sion criteria were designed to capture sick neonates at significant 
risk for AKI and those who had an expected hospitalization 
of at least 48  h. Infants receiving routine care in the newborn 
nursery were not included in this study. The exclusion criteria 
were designed to omit patients with a limited hospitalization in 
the NICU or who had significant incomplete data particularly in 
the first 2 weeks of life. This exclusion is based on the belief that 
the first 2 weeks of life encompass a critical at-risk time for AKI. 
Because of the variable center-specific practice patterns regarding 
newborns with congenital heart disease requiring surgical repair 
(i.e., transfer to the PICU for post-operative care) and because 
these infants have been the subject of a number of previous 
AKI studies, neonates who required cardiac surgery within 
7 days of birth were excluded. Infants with isolated ventricular 
septal defect, atrial septal defect, or patent ductus arteriosus were 
included unless they were transferred out of the NICU <7 days 
for surgical repair. Premature infants who remained in the NICU 
for ≥7 days to gain weight and grow in preparation for surgery 
were also included.
All neonates admitted to the participating NICUs were screened 
for inclusion criteria. Demographic data including sex, self-reported 
tablE 5 | inclusion and exclusion criteria.
inclusion criteria Exclusion criteria
• Admitted to 
participating NICU 
between 1/1/14 and 
3/31/14
• ≥48 h of IV fluids
• Age greater than 14 days at admission
• Congenital heart disease with surgery <7 days of life
• Lethal chromosomal anomaly; including trisomy 
13, 18 and anencephaly 
• Neonatal mortality <48 h
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ethnicity, race, date of birth, and date of NICU admission were col-
lected for all neonates (Supplementary Materials – Data Sheet 1 – 
Screening Form). Date of birth was required as an “anchor” for the 
database format and the generation of the appropriate daily and 
weekly forms and was designated as “day 1.”
Variable Collection
The AWAKEN study was designed to acquire information that 
is most likely related to kidney function and kidney injury in 
critically ill neonates. All sCr values during the study period 
were recorded. Data collection was otherwise organized into five 
components. Case report forms (CRF) and manual of operations 
are included in Supplementary Materials, Data Sheet 2.
Baseline Demographics
Maternal characteristics including age, gravid, parity, health 
conditions (chronic and pregnancy-associated), peri-partum 
infections, complications, and medications received; neonatal 
characteristics including site of delivery (inborn or outborn), 
mode of delivery, gestational age and birthweight, length and 
head circumference, initial temperature, resuscitation data, and 
reasons for admission.
Daily Information for Week 1
Weight, blood pressure and heart rate, highest level of respiratory 
support, fluid intake (intravenous and enteral fluids), fluid output 
(urine output and total), nephrotoxic medications, and laboratory 
parameters (hemoglobin, blood urea nitrogen, sodium, albumin, 
blood cultures, urine cultures, and cerebrospinal fluid cultures).
Weekly “Snapshots” for the Remaining Weeks of 
Data Collection
The first value of the week for all of the variables included in the 
daily form until the neonate reached the endpoint.
Discharge Data
Disposition of the infant at the end of the data collection period 
(“status” – discharged home prior to 120 days, still in the NICU 
at ≥120 days, transferred to another facility for convalescent care, 
transferred to another facility for escalation of care or died on 
or prior to 120 days), growth parameters, discharge medications 
if kidney related (urinary tract infection prophylaxis, antihy-
pertensive medications and diuretics), and discharge diagnoses. 
Detailed information about kidney diagnoses (congenital abnor-
malities, episodes of AKI and need for nephrology consults) and 
renal replacement therapy provided were collected.
Prolonged Length of Stay
Date of final disposition and reason for prolonged NICU stay 
>120 days were collected, as were the highest and last creatinine 
obtained between 120 days and final disposition.
Because this is a retrospective study, all data reflect current, 
local standards of care. Definitions of terms listed in the Manual 
of Procedures were evidence-based whenever possible or consist-
ent with those used in other published research studies.
MediData Rave™
Data entry of the variables of interest was performed by participat-
ing sites using a web-based database, MediData Rave™. Rave™ is a 
commercially available system designed to capture, manage, and 
report clinical research data. Through this system, each participat-
ing site was assigned a unique code by the database management 
team. If responses to the initial inclusion and exclusion criteria 
provided by the individual performing the data entry fulfilled 
study criteria, the system dynamically generated the remainder 
of the patient casebook, opening the “gateway” for the site to 
enter additional data for an enrolled patient. When eligibility was 
determined, the system guided the data entry personnel at each 
site to enter the clinical variables of interest. Limited protected 
health information (date of birth) was required to generate the 
proper dates for the daily and weekly forms. Release of the date of 
birth as part of the limited data set was agreed upon in the Data 
Use Agreement between each site and the primary study site. All 
participating sites used the same case report forms (CRFs). The 
electronic CRFs were designed, in partnership with the project’s 
Database Committee, by the representatives in the Cincinnati 
Children’s Hospital Medical Center Data Management Center 
(CCHMC DMC). Data entered by the sites were reviewed by 
the DMC. Values outside of expected ranges generate queries 
back to the individual site personnel. Query responses are then 
reviewed by the DMC personnel as well as physician members of 
the database subcommittee if clinical expertise was required to 
adjudicate the responses.
All site primary investigators and site personnel performing 
data entry completed commercially developed online training 
prior to being allowed access to MediData Rave™. Additional 
webinars sponsored by primary site personnel and Database 
 Committee team were conducted to instruct sites on the proper 
use and interpretation of the Manual of Procedures (includ-
ing definitions for study variables) and completion of CRFs. 
Co-chairs of the database committee and the lead coordinator 
were available for guidance and clarification as needed.
analyses
Data management and statistical analysis will be executed at the 
University of Alabama at Birmingham using SAS software v9.4 
(SAS Institute, Cary, NC, USA). Analysis of data will be performed 
independently for each specific aim. Descriptive statistics will be 
used to describe the populations of NICU patients overall, with 
and without AKI. Data will be analyzed to compare the different 
definitions of neonatal AKI.
interventions
No interventions are included in this study protocol.
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Co-Enrollment
No conflict with any other ongoing studies as this is a retrospec-
tive observational study.
timeline
The MediData Rave™ database was piloted by centers from 
1/17/15 to 1/28/15. Subsequently final adjustments of the 
manual of operation were made. Each institution was required 
to participate in database training on either 2/10/15 or 2/12/15. 
Additionally, each database entry personnel was required to par-
ticipate in online training from 2/10/15 to 2/27/15. The database 
was open for data entry on 3/2/15. The trial was registered at 
ClinicalTrials.gov on 5/11/15. All institutions completed data 
entry by 12/12/15.
diSCuSSion
The AWAKEN study created the largest cohort of neonates 
assembled to date for exploring AKI in this vulnerable patient 
population. Across the 24 centers with high acuity NICUs dis-
tributed across 3 continents and 4 countries, we screened 4273 
and enrolled 2162 newborns during the 3 months’ time-period. 
As demonstrated in Table 2, the institutions represented in the 
AWAKEN study include academic medical centers with diverse 
referral patterns, volumes of patients and creatinine assay meth-
ods. By collecting detailed demographic information on these 
babies, the NKC has created a rich database with which we will 
be able to describe the prevalence of neonatal AKI in different 
ethnic, racial, and geographic populations. Analyses can be per-
formed based on birthweight, gestational age, and other criteria. 
Daily weights can be assessed as a surrogate for “fluid balance” in 
the first week after birth in ELBW neonates given the difficulty 
in accurately determining fluid status based solely on intake and 
measurable output. Although data points were chosen based on 
relatedness to renal function and injury, the database will be a 
source of carefully collected information on NICU patients that 
may be used to compare practices across sites and investigate 
various best practices in this population, including strategies for 
fluid provision.
The NKC represents an interdisciplinary group of clinicians 
and researchers interested in neonatal AKI with the unified 
goal of improving the lives, health and wellbeing of newborns 
at risk for kidney disease. Representation of institutions from 
four countries and three continents and the involvement of both 
pediatric nephrologists and neonatologists make the unique. 
Each subspecialty brings its expertise relevant to understanding 
the problem of neonatal renal development, function, and injury. 
For example neonatologists have less experience with the long-
term ramifications of renal disorders seen in the newborn period, 
while pediatric nephrologists rarely are involved in the initial 
care of the extremely premature infants or those with severe 
perinatal asphyxia, including decisions regarding fluid provision 
and choice of drugs to treat or prevent various conditions. True 
collaborations such as this will allow a greater understanding of 
neonatal renal physiology and pathology and the impact on other 
organ systems. AWAKEN will provide the infrastructure and 
experience for gathering evidence-based data on best practices 
to improve short- and long-term kidney health in neonates.
The AWAKEN study does have several limitations, the most 
substantial being the retrospective design. The retrospective 
design will likely result in the absence of data points for many 
infants. Since the serum creatinine is ordered by the treating 
neonatologist who may be more likely to do so if there are 
clinical indicators for AKI, its incidence may be underestimated 
especially as AKI in neonates may be non-oliguric as in the case 
of gentamicin nephrotoxicity. However, we will gain insight 
into current practices for monitoring, diagnosing, and treating 
kidney function. By comparing practices between NICUs, we 
will acquire a sense of important time points for data collection 
for future prospective studies. In addition, we may be able to 
develop “best practices” standards of care for at-risk neonatal 
populations.
At the onset of the AWAKEN project the database committee, 
in conjunction with the Steering committee, scrutinized variables 
to address the aims of the study, with the goal of balancing the 
granularity of the data with the time commitment necessary for 
data extraction and entry. Even after limiting collection to those 
data points deemed crucial, the time required to complete screen-
ing and data entry for excluded patients was ~30  min and an 
average of 2 h for included patients, depending on the complexity 
of the medical conditions and length of stay.
As with many clinical studies, retrospective or prospective, 
much of the data extraction is done by trained research staff 
and not by physicians. We surveyed the participating centers 
and discovered the site principal investigator was responsible 
for a significant proportion of data extraction at only four 
institutions, and the data was entered by a physician at only 
two sites. In fact, since this was a study initiated without benefit 
of external funding, it is likely that the extent of direct physi-
cian involvement in the data extraction and entry was higher 
than if funding were available to hire additional research staff. 
Given the cross-disciplinary nature of the study, the familiar-
ity of research staff with both neonatal and renal terminology, 
including definitions of diagnoses, may have been challenging. 
Several illustrative examples were encountered as the database 
was “cleaned” and queries generated. This unfamiliarity resulted 
in additional time and effort on the part of the center PI, the 
database committee and the data center personnel to ensure 
the integrity of the data prior to analysis. In future studies, 
more detail and training will be incorporated in the Manual of 
Procedures to address this issue.
Even with these limitations, NKC has an unprecedented 
opportunity to provide better estimates of the incidence and out-
comes of neonatal AKI, and it is likely this work will help to refine 
the definition of neonatal AKI, improve our understanding of the 
risk factors associated with AKI, and raise awareness of AKI as an 
important clinical event during the care of critically ill neonates. 
We will improve our understanding of the contribution of fluid 
balance to biochemical and clinical outcomes. Additionally, by 
having a concise documentation of each infant’s hospital course, 
we will be able to infer the role which AKI and other potential 
risk factors have on the incidence of CKD in future studies. 
These collaborations, including the data and infrastructure, will 
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enable the NKC to plan future intervention studies geared toward 
the reduction of AKI and improved short and long-term renal 
outcomes, including CKD.
EtHiCS and diSSEMination
Ethics approval and Consent to 
Participate
AWAKEN was proposed as human subjects research. The study 
design allowed for a waiver of informed consent/parental permis-
sion. Permission for limited protected health information (PHI) 
dataset was requested and granted by all sites, specifically to 
allow the use of date of birth for proper creation of the database 
as described above. The waiver of consent was pursued based on 
the following rationale:
•	 The research involves no more than minimal risk to the 
subjects.
•	 The waiver does not adversely affect the rights and welfare of 
the subjects.
•	 The research cannot practically be carried out without the 
waiver or alteration. This is a retrospective cohort study of 
infants admitted over a year prior to data collection. Requiring 
informed consent from every eligible patient would cause a 
significant reduction in enrollment and potentially introduce 
selection bias into the dataset.
The sites participating in AWAKEN obtained appropriate 
institutional review board approval from their respective centers 
and executed data use agreements with the data coordination 
center (Cincinnati Children’s Hospital Medical Center). Protocol 
amendments have been generated by the protocol committee and 
disseminated to each institution.
access to data and dissemination
Deidentified data is maintained at the University of Alabama at 
Birmingham. NKC investigators plan to disseminate data through 
peer-reviewed publications and through platform and poster 
presentations at educational conferences. The ancillary studies 
committee will provide data sets to NKC members following the 
approval of the project.
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